ACADIA Pharmaceuticals Q2 EPS $0.01 Beats $(0.08) Estimate, Sales $165.24M Beat $157.81M Estimate
Portfolio Pulse from Benzinga Newsdesk
ACADIA Pharmaceuticals reported Q2 earnings of $0.01 per share, beating the analyst consensus estimate of $(0.08) by 112.5%. The company also reported quarterly sales of $165.24 million, beating the analyst consensus estimate of $157.81 million by 4.71%. This represents a 104.76% increase in earnings and a 22.79% increase in sales compared to the same period last year.
August 04, 2023 | 12:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ACADIA Pharmaceuticals' Q2 earnings and sales beat estimates, indicating a strong financial performance. This could potentially lead to a positive impact on the company's stock.
ACADIA Pharmaceuticals' Q2 earnings and sales exceeded analyst estimates, which is typically a positive signal for investors and can lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100